[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Gómez Vázquez M, Peteiro C, Toribio J: Neutrophilic eccrine hidradenitis heralding the onset of chronic myelogenous leukaemia. J Eur Acad Dermatol Venereol; 2003 May;17(3):328-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophilic eccrine hidradenitis heralding the onset of chronic myelogenous leukaemia.
  • Neutrophilic eccrine hidradenitis was initially described in acute myelogenous leukaemic patients undergoing chemotherapy, suggesting a drug-induced mechanism.
  • However, most the reported cases have been described in acute myelogenous leukaemic cases receiving chemotherapy.
  • We describe a neutrophilic eccrine hidradenitis case unassociated with chemotherapy in a woman with chronic myelogenous leukaemia.
  • [MeSH-major] Hidradenitis / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Axilla. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12702078.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


2. Yoshida C, Kojima H, Iijima T, Katsura Y, Shimizu S, Suzukawa K, Mukai HY, Hasegawa Y, Abei M, Nagasawa T: Association of non-alcoholic steatohepatitis (NASH) with chronic neutrophilic leukemia. Eur J Haematol; 2004 Mar;72(3):225-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of non-alcoholic steatohepatitis (NASH) with chronic neutrophilic leukemia.
  • A 54-yr-old female having chronic neutrophilic leukemia (CNL) associated with severe liver injury is presented.
  • There was no abnormality in serum cholesterol, triglyceride, or glucose levels.
  • As the patient had no history of alcohol abuse, a diagnosis of non-alcoholic steatohepatitis (NASH) was made.
  • Assuming that the infiltration of abnormal neutrophils into the liver contributed to the development of NASH, she was treated with cytoreductive chemotherapy (cytosine arabinoside: 100 mg/d, 1-3 doses/wk).
  • To our knowledge, this is the first report describing the development of NASH in a myeloproliferative disorder.
  • [MeSH-major] Fatty Liver / etiology. Leukemia, Neutrophilic, Chronic / complications
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Biopsy. Cytarabine / therapeutic use. Female. Humans. Middle Aged. Treatment Outcome


3. Piliotis E, Kutas G, Lipton JH: Allogeneic bone marrow transplantation in the management of chronic neutrophilic leukemia. Leuk Lymphoma; 2002 Oct;43(10):2051-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic bone marrow transplantation in the management of chronic neutrophilic leukemia.
  • Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative disorder characterized by a clonal proliferation of mainly mature neutrophils, which is often difficult to differentiate from reactive leukocytosis or other myeloproliferative disorders.
  • Treatment to date has focused on disease control rather than cure.
  • Once the disease has progressed to a more aggressive leukemia there is typically little chance of obtaining a long lasting remission due to the older age of most patients as well as the acquisition of multiple poor prognostic cytogenetic abnormalities.
  • In this case report we describe a successful sibling allogeneic bone marrow transplant in a 60-year-old man with CNL performed while he was still in the stable phase of his disease.
  • We propose that even in older patients this curative approach may be considered in selected patients at an early stage of their disease, similar to the approach taken with chronic myelogenous leukemia.
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Neutrophilic, Chronic / therapy
  • [MeSH-minor] Disease Management. Disease-Free Survival. Graft Survival. Graft vs Host Disease / drug therapy. Humans. Male. Middle Aged. Transplantation, Homologous


Advertisement
4. You Y, Li QB, Chen ZC, Li WM, Xia LH, Zhou H, Zou P: Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation. Chin Med J (Engl); 2008 Sep 20;121(18):1770-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
  • BACKGROUND: Relapse remains an obstacle to successful allogeneic haematopoietic stem cell transplantation (allo-HSCT) for patients with acute leukaemia and no standard treatment is available.
  • We assessed fludarabine and cytarabine with transfusion of donor haematopoietic stem cell in treating the relapse of acute leukaemia after allo-HSCT.
  • METHODS: Seven patients, median age 34 years, with relapse of acute leukaemia after allo-HSCT received combination chemotherapy of fludarabine with cytarabine for 5 days.
  • Five patients suffered from acute myeloid leukaemia (2 refractory) and 2 refractory acute lymphoblastic leukaemia.
  • After the transplantation, the median relapse time was 110 days (range, 38 - 185 days).
  • Two days after chemotherapy, 5 patients received infusion of donor's peripheral blood stem cells, mobilized by granulocyte colony stimulating factor.
  • DNA sequence analysis at day 30 after treatment identified all as full donor chimera type.
  • The median observation time was 189 days.
  • After the treatment, the median time for neutrophilic granulocyte value = 0.5 x 10(9)/L and for platelet value = 20 x 10(9)/L were 13 days (range, 10 - 18 days) and 15 days (range, 11 - 24 days), respectively.
  • Graft versus host disease occurred in 2 patients (acute) and 3 (chronic).
  • The other patients died of leukaemia related deaths.
  • Three patients with chronic graft versus host disease who had received donor peripheral blood stem cells reinfusion have survived for 375 days, 232 days and 195 days, respectively.
  • CONCLUSIONS: Fludarabine with cytarabine plus the donor haematopoietic stem cell should be considered as an effective therapeutic regimen for relapse of acute leukaemia after allo-HSCT.
  • The disease free state of patients may increase, though with high risk of secondary fungal infection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080355.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


5. Elliott MA, Dewald GW, Tefferi A, Hanson CA: Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia; 2001 Jan;15(1):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study.
  • This report describes a single institution's recent experience with six patients fulfilling the diagnostic criteria of chronic neutrophilic leukemia.
  • Two patients demonstrated clonal evolution during the course of the disease.
  • All responded initially to therapy with hydroxyurea with control of leukocytosis and reduction in splenomegaly.
  • Aggressive chemotherapy to control progressive leukocytosis resulted in death due to cytopenias in two of these patients.
  • The third patient received less intensive chemotherapy and died of progressive disease.
  • One patient died after transformation of the disease into undifferentiated acute myeloid leukemia.
  • Two patients remain alive with stable disease on hydroxyurea therapy, 12 and 54 months after initial diagnosis.
  • Chronic neutrophilic leukemia is a rare clinicopathologic entity that can be distinguished from chronic myelogenous leukemia, the recently described neutrophilic-chronic myelogenous leukemia, and myelodysplastic syndrome.
  • The clinical course is heterogeneous, with a definite risk of death from either blastic transformation or progressive neutrophilic leukocytosis.
  • [MeSH-major] Leukemia, Neutrophilic, Chronic

  • Genetic Alliance. consumer health - Chronic Neutrophilic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11243396.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 20
  •  go-up   go-down


6. Gning SB, Debonne JM, Diagne-Guèye NM, Ndiaye B, Fall F, Mbaye PS: [Leg ulcer due to hydroxyurea. A case report]. Dakar Med; 2006;51(2):89-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Ulcère de jambe lié a l'hydroxyurée. A propos d'une observation.
  • She was followed since 2001 for a chronic myelogenous leukaemia, and took hydroxyurea at a rate of 1500 mg per day, with a good clinical and hematologic answer.
  • The hemogram showed a hyperleucocytosis with 24.000 white elements/mm3 with neutrophilic polynucleosis.
  • Its occurrence imposes the final stop of the treatment.
  • [MeSH-minor] Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Middle Aged

  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17632983.001).
  • [ISSN] 0049-1101
  • [Journal-full-title] Dakar médical
  • [ISO-abbreviation] Dakar Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Senegal
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


7. Willard RJ, Turiansky GW, Genest GP, Davis BJ, Diehl LF: Leukemia cutis in a patient with chronic neutrophilic leukemia. J Am Acad Dermatol; 2001 Feb;44(2 Suppl):365-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia cutis in a patient with chronic neutrophilic leukemia.
  • Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative disorder.
  • We report the first case of CNL with an associated leukemia cutis.
  • CNL was diagnosed in a 74-year-old white woman in 1998, based on neutrophilic infiltration of the bone marrow and absence of the Philadelphia chromosome.
  • The patient presented to the dermatology service in August 1998 with a 2-week history of a pruritic eruption on the arms, hands, and legs.
  • Leukemia cutis was demonstrated on biopsy specimens of several lesional sites.
  • The eruption progressed, despite treatment with topical and systemic corticosteroids.
  • Treatment with systemic chemotherapy did affect partial resolution of the eruption, with parallel decreases in bone pain and white blood cell count, but the disease progressed and the patient ultimately died 5 months after her initial skin findings.
  • Only one other case of CNL with dermatologic manifestations has been reported, CNL associated with a reactional neutrophilic dermatosis.
  • The importance of distinguishing the specific infiltrates of leukemia from the nonspecific infiltrates of reactional dermatoses, such as Sweet's syndrome, is illustrated.
  • [MeSH-major] Leukemia / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Skin / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Bone Marrow Cells / pathology. Disease Progression. Fatal Outcome. Female. Hand Dermatoses / diagnosis. Humans. Leg Dermatoses / diagnosis






Advertisement